Combioxin SA, a clinical-stage biotech company developing innovative anti-virulence drugs, has secured a $1.2M grant to advance its work against severe bacterial infections. The funding will support the company's efforts to combat the escalating threat of antibiotics resistance.
The company is focused on a novel approach to tackle superbugs, developing therapies that target the mechanisms bacteria use to cause disease, rather than directly killing them. This strategy aims to reduce the selective pressure that often leads to drug resistance, offering a new front in a critical global health battle.
